Immunogenicity of Guselkumab Is Not Clinically Relevant in Patients with Moderate-to-Severe Plaque Psoriasis
- 1 August 2019
- journal article
- letter
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 139 (8) , 1830-1834.e6
Abstract
No abstract availableFunding Information
- Johnson & Johnson Innovative Medicine (BR)
This publication has 4 references indexed in Scilit:
- Safety of guselkumab in patients with moderate‐to‐severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studiesBritish Journal of Dermatology, 2018
- Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trialJournal of the American Academy of Dermatology, 2017
- Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trialJournal of the American Academy of Dermatology, 2017
- Antibody Pharmacokinetics and PharmacodynamicsJournal of Pharmaceutical Sciences, 2004